Literature DB >> 21255096

New targets of pemphigus vulgaris antibodies identified by protein array technology.

Mina Kalantari-Dehaghi, Douglas M Molina, Mandana Farhadieh, W John Morrow, Xiaowu Liang, Philip L Felgner, Sergei A Grando.   

Abstract

We performed partial evaluation of pemphigus vulgaris (PV) autoantibody profile using the protein array technology. The sera from seven patients with acute PV and five healthy donors were probed for the presence of autoantibodies characteristic of the organ-non-specific autoimmune disorders rheumatoid arthritis, lupus erythematosus, scleroderma, diabetes and some other autoimmune disorders, but not to desmosomal proteins. The array targeted 785 human genes amplified using Mammalian Gene Clone Collection with gene-specific primers containing 20-bp nucleotide extension complementary to ends of linear pXT7 vector. The array identified PV antibodies significantly (P<0.05) differentially reactive with 16 antigens, most of which were cell-surface proteins, such as CD2, CD31, CD33, CD36, CD37, CD40, CD54, CD66c and CD84 molecules, nicotinamide/nicotinic acid mononucleotide adenylyltransferase, immunoglobulin heavy chain constant region gamma 2 and others. Reactivity with Fc-IgG helps explain an ability of the chimeric desmoglein constructs to absorb out all disease-causing PV antibodies. Anti-M(1) muscarinic receptor antibody was also identified, consistent with the facts that while blockade of this receptor causes keratinocyte detachment, its activation is therapeutic in PV. Further proteomics analysis of PV antibodies should help elucidate the immunopathogenic mechanisms underlying keratinocyte detachment and blistering.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255096     DOI: 10.1111/j.1600-0625.2010.01193.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

1.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering.

Authors:  Volker Spindler; Vera Rötzer; Carina Dehner; Bettina Kempf; Martin Gliem; Mariya Radeva; Eva Hartlieb; Gregory S Harms; Enno Schmidt; Jens Waschke
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

3.  Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies.

Authors:  Mina Kalantari-Dehaghi; Yumay Chen; Wu Deng; Alex Chernyavsky; Steve Marchenko; Ping H Wang; Sergei A Grando
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

Review 4.  A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases.

Authors:  Li Liang; Philip L Felgner
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

Review 5.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

Review 6.  The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the "Super Compensation Hypothesis".

Authors:  Animesh A Sinha; Thomas Sajda
Journal:  Front Med (Lausanne)       Date:  2018-08-14

Review 7.  Phenotyping of Adaptive Immune Responses in Inflammatory Diseases.

Authors:  Jens Y Humrich; Joana P Bernardes; Ralf J Ludwig; David Klatzmann; Alexander Scheffold
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

8.  Pemphigus vulgaris autoantibody profiling by proteomic technique.

Authors:  Mina Kalantari-Dehaghi; Grant J Anhalt; Michael J Camilleri; Alex I Chernyavsky; Sookhee Chun; Philip L Felgner; Algis Jasinskas; Kristin M Leiferman; Li Liang; Steve Marchenko; Rie Nakajima-Sasaki; Mark R Pittelkow; John J Zone; Sergei A Grando
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.